Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Allelic and genotypic distribution of BAFF -871T/C among patients with early rheumatoid arthritis, undifferentiated arthritis, and controls

From: Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort

BAFF -871T/Caia Early RA UA Controls P value Odds ratio (95% CI) P value Odds ratio (95% CI)
Allele frequencies n = 1,112 n = 260 n = 180   Early RA versus UA   Early RA versus controls
-871C (%) 603 (54) 146 (56) 90 (50) NS 1.00 (0.77–1.30) NS 1.18 (0.86–1.62)
-871T (%) 509 (46) 114 (44) 90 (50)     
Genotype frequencies n = 556 n = 130 n = 90     
CC (%) 171 (31) 43 (33) 21 (23) NS 1.02 (0.68–1.53)
CC versus CT and TT
NS 1.46 (0.87–2.46) CC versus CT and TT
CT (%) 261 (47) 60 (46) 48 (54)     
TT (%) 124 (22) 27 (21) 21 (23) NS 1.02 (0.66–1.60)
TT versus CT and CC
NS 0.94 (0.56–1.60) TT versus CT and CC
  1. Comparisons used chi-square test. BAFF, B-cell activating factor of the tumor necrosis factor family; CI, confidence interval; NS, not significant; RA, rheumatoid arthritis; UA, undifferentiated arthritis.